1. Home
  2. DCGO vs ACRV Comparison

DCGO vs ACRV Comparison

Compare DCGO & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DocGo Inc.

DCGO

DocGo Inc.

HOLD

Current Price

$0.70

Market Cap

67.0M

Sector

Health Care

ML Signal

HOLD

Logo Acrivon Therapeutics Inc.

ACRV

Acrivon Therapeutics Inc.

HOLD

Current Price

$1.60

Market Cap

56.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DCGO
ACRV
Founded
2015
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Managed Health Care
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
67.0M
56.5M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
DCGO
ACRV
Price
$0.70
$1.60
Analyst Decision
Strong Buy
Buy
Analyst Count
3
6
Target Price
$3.33
$13.00
AVG Volume (30 Days)
874.8K
3.4M
Earning Date
02-26-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$368,093,385.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$805.34
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.66
$1.05
52 Week High
$5.68
$8.00

Technical Indicators

Market Signals
Indicator
DCGO
ACRV
Relative Strength Index (RSI) 30.80 35.86
Support Level $0.74 $1.57
Resistance Level $0.80 $2.01
Average True Range (ATR) 0.06 0.14
MACD -0.01 -0.02
Stochastic Oscillator 11.37 0.00

Price Performance

Historical Comparison
DCGO
ACRV

About DCGO DocGo Inc.

DocGo Inc is a provider of last-mile mobile health services and integrated medical mobility solutions. The company uses its care delivery platform to provide mobile health services, virtual care management, and ambulance services. It has three reporting segments: Mobile Health Services, Transportation Services, and Corporate. A majority of its revenue is generated from the Mobile Health Services segment, which includes various healthcare services performed at homes, offices, and other locations and event services such as on-site healthcare support at sporting events and concerts. Geographically, the company generates a majority of its revenue from the United States and the rest from the United Kingdom.

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

Share on Social Networks: